• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


295.900 DKK 0.500 0.17%

As of 11:01:42 ET on 11/27/2014.

Snapshot for Genmab A/S (GEN)

Open: 297.000 Day's Range: 295.500 - 299.500 Volume: 206,099
Previous Close: 295.400 52wk Range: 180.100 - 299.500 1-Yr Rtn: +33.77%

Stock Chart for GEN

No chart data available.
  • GEN:DC 295.900
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 55.3084
Estimated P/E(12/2014) 50.5466
Relative P/E vs. KFX 2.6793
Earnings Per Share (DKK) (ttm) 5.3500
Est. EPS (DKK) (12/2014) 5.8540
Est. PEG Ratio 1.0601
Market Cap (M DKK) 16,856.66
Shares Outstanding (M) 56.97
30 Day Average Volume 220,423
Price/Book (mrq) 8.6956
Price/Sale (ttm) 18.9402
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/02/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil